HCC
CLDX icon

Hirtle Callaghan & Co’s Celldex Therapeutics CLDX Stock Holding History

Hirtle Callaghan & Co’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-233
Closed -$64K – 78
2014
Q4 		$64K Buy
+233
New +$57.9K 0.01% 269

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hirtle Callaghan & Co's CLDX Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of Celldex Therapeutics (CLDX) in Q1 2015, closing a stake of 233 shares — an estimated $64K sold.

Hirtle Callaghan & Co first reported a position in CLDX in Q4 2014 and held it in 1 quarter. The position peaked at $64K in Q4 2014. 193 funds tracked by Wall St. Rank hold CLDX as of Q1 2015.

  • Hirtle Callaghan & Co reported no remaining Celldex Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 233 Celldex Therapeutics shares in Q1 2015, an estimated $64K.
  • Hirtle Callaghan & Co first reported a position in Celldex Therapeutics in Q4 2014 and held it in 1 quarter.
  • Hirtle Callaghan & Co's Celldex Therapeutics position peaked at $64K in Q4 2014.
  • 193 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.